Olzapin Tablet 2.5 mg (Olanzapine)

Adult dose

The therapeutic dose of this medicine should be adjusted according to the patient's clinical condition. Increases above the usual recommended daily dose of 10 mg are recommended only after an appropriate clinical evaluation. Schizophrenia: The recommended initial dose is 5∼10 mg of olanzapine once daily. Maintenance treatment of schizophrenia: Efficacy was demonstrated in a placebo-controlled study in patients with schizophrenia whose symptoms had stabilized after taking this medicine for approximately 8 weeks and who received maintenance treatment for 8 months at doses of 10∼20 mg daily. The need for maintenance treatment at an appropriate dose should be assessed periodically. Treatment of manic and mixed episodes associated with bipolar I disorder: The initial dose is 15 mg once daily as monotherapy, or 10 mg once daily as adjunctive therapy with lithium or valproate. Prevention of recurrence in bipolar disorder: The recommended initial dose is 10 mg once daily. Patients who have been taking this medicine to treat mania should continue the same dose to prevent recurrence. If a new manic, mixed, or depressive episode occurs, treatment with this medicine should continue, together with adjunctive therapy to treat mood symptoms as clinically indicated (with the dose optimized as needed). Treatment of schizophrenia and manic and mixed episodes associated with bipolar I disorder, and prevention of recurrence in bipolar disorder: The daily dose may be adjusted within the range of 5 mg to 20 mg based on the clinical condition. Increases above the recommended initial dose are recommended only after an appropriate clinical evaluation, and the dose should generally be increased at intervals of 24 hours or longer. If treatment with this medicine is discontinued, the dose should be reduced gradually and cautiously. Acute treatment of depressive episodes associated with bipolar I disorder: Start treatment with olanzapine 5 mg once daily and increase to 10 mg once daily. Administer this medicine at bedtime and adjust the dose as appropriate according to age and symptoms, but do not exceed a daily dose of 20 mg. Older adults: Starting at a dose of 5 mg or less daily may be considered when there is sufficient evidence based on clinical factors. Patients with renal or hepatic impairment: A low initial dose (5 mg) should be considered. In moderate hepatic impairment (cirrhosis, Child-Pugh class A or B), the initial dose is 5 mg and should be increased cautiously. Patients with multiple factors that delay the metabolism of this medicine (female sex, older age, and nonsmoking status) may also be started at a low dose.

This medication can rarely cause life-threatening neuroleptic malignant syndrome, so if symptoms such as high fever, muscle rigidity, or changes in mental status occur, immediate medical attention should be sought. This medication is not approved for use in dementia patients, and especially in elderly dementia patients, there may be an increased risk of mortality and cerebrovascular disorders, so use should be avoided. Prolonged use may result in movement disorders, such as tardive dyskinesia; if unusual movements occur, dosage adjustment or discontinuation should be considered. This medication can affect blood glucose control and worsen diabetes, so diabetic patients or those at risk should regularly monitor their blood glucose and weight. Sudden discontinuation may cause withdrawal symptoms such as insomnia, anxiety, and nausea, so it is safer to taper down gradually when discontinuing. In patients with heart disease or the elderly, hypotension, cardiac arrhythmia, and orthostatic hypotension may occur, so caution is necessary, and regular monitoring of blood pressure and cardiac status is recommended. Pregnant or breastfeeding women should consult a doctor before using this medication as it may affect the fetus or newborn. There may be interactions with other medications, especially those metabolized in the liver; patients should inform healthcare providers of all medications they are taking. Caution should be exercised when driving or operating dangerous machinery, as drowsiness or dizziness may occur. This medication easily disintegrates in the mouth, so it should be taken immediately with water or juice. Blood tests may show decreased white blood cell counts, so if symptoms of infection arise, immediate consultation with a healthcare provider is necessary. During the use of this medication, regular liver function tests and blood tests are important to check for any abnormalities.

• High fever
• muscle rigidity
• altered mental status
• irregular pulse
• changes in blood pressure
• tachycardia
• sweating
• cardiac arrhythmia
• elevated creatine phosphokinase
• myoglobinuria

This medication should be stored in a tightly sealed container to prevent exposure to air, and it is best to keep it at room temperature between 15°C and 30°C. Proper storage will help maintain the efficacy of the medication and prevent degradation.

Appearance

White round film-coated tablet

Package unit

30 tablets (10 tablets/Alu-Alu×3)